Pyogenic Granuloma on Facial Skin Associated With Long-Term Topical Application of Tacrolimus
Pyogenic granuloma ans tacrolimus
Pyogenic granuloma (PG) is a benign vascular neoplasm of the skin and mucous membranes, the exact cause and pathogenesis of which still remain unknown. PG typically occurs in the form of solitary and rarely multiple, rapidly developing, glistering, hemorrhagic and ulceration-prone, pink or purple, angiomatous papule or nodule. Proposed stimuli for the occurrence of PG include minor trauma and chronic irritation, infections, viral oncogenes, pregnancy, microscopic arteriovenous anastomoses and diverse drugs. Tacrolimus is a macrolide, produced by the Streptomyces Ttsukubaensis, which exerts potent immunosuppressive action through inhibition of calcineurin. Topically applied tacrolimus has been approved for the treatment of patients with moderate to severe atopic dermatitis unresponsive or intolerant to conventional regimens, but it has also been used as an off-label treatment for various cutaneous diseases. We report a 35-year-old man who developed PG on his face after a long-term topical application of tacrolimus ointment for the treatment of seborrheic dermatitis. The patient didn’t recall any trauma or other chronic irritation at the site of his recently emerging solitary lesion, whereas other predisposing factors for PG were excluded. To the best of our knowledge the case presented here is the first report of this adverse reaction. PG should be considered as a possible side-effect of topical application of tacrolimus and dermatologists should be able to diagnose and properly treat it.
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).